Sign Out
Differentiated Thyroid Cancer: LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma: LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
Hepatocellular Carcinoma: LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Endometrial Carcinoma: LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by a validated test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Patient Selection under Dosage & Administration].
